{"id":"NCT01566162","sponsor":"Sumitomo Pharma America, Inc.","briefTitle":"A Twelve Week, Open Label Extension Study in Patients With Schizophrenia","officialTitle":"A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-04","primaryCompletion":"2013-11","completion":"2013-11","firstPosted":"2012-03-29","resultsPosted":"2014-11-20","lastUpdate":"2019-04-09"},"enrollment":191,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenia"],"interventions":[{"type":"DRUG","name":"Lurasidone","otherNames":[]}],"arms":[{"label":"Lurasidone","type":"EXPERIMENTAL"}],"summary":"This is a 12-week, multi-center, open-label extension study designed to evaluate the longer-term safety, tolerability and effectiveness of lurasidone for the treatment of subjects with schizophrenia.","primaryOutcome":{"measure":"Safety - Treatment-emergent Adverse Events (TEAEs), TEAEs Leading to Discontinuation, and Serious AEs (SAEs)","timeFrame":"12 weeks","effectByArm":[{"arm":"Lurasidone","deltaMin":72,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":3},"locations":{"siteCount":63,"countries":["United States","France","Italy","Russia","Serbia","Slovakia","South Africa"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":13,"n":191},"commonTop":["Akathisia","Schizophrenia","Nasopharyngitis","Diarrhoea","Nausea"]}}